RTTNews | Sep 20, 2021 10:51AM EDT

10:50 Monday, September 20, 2021 (RTTNews.com) - BeyondSpring Inc. (BYSI) shares are sliding more than 19 percent on Monday morning trade, despite the pharma company with a special focus on cancer therapeutics announced positive results for its phase 3 DUBLIN -3 study with Plinabulin/Docetaxel combination. The company said the study met the primary endpoint showing statistically significant improvement in overall survival for the combination versus docetaxel in second/third-line non-small cell lung cancer patients. The study also met key secondary endpoints showing statistically significant improvement for the combination versus docetaxel. The trial of Plinabulin, a selective immunomodulating microtubule-binding agent, and a potent antigen-presenting cell inducer, has enrolled 559 2nd/3rd line non-small cell lung cancer patients with a measurable lung lesion.

BeyondSpring said there were a significant reduction in the incidence of Grade 4 neutropenia and clinically meaningful relative improvement in Q-TWiST of 18.4%.

Currently, shares are at $18.38, down 19.77 percent from the previous close of $22.91. The shares had surged to reach a year-to-date high at the end of August and the stock has been declining since then.

Read the original article on RTTNews ( https://www.rttnews.com/3226908/beyondspring-down-despite-positive-results-for-plinabulin-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved